J.P. Morgan analysts said the findings of J&J’s investigation “could significantly hinder the product’s rollout in the U.S. and globally” and lead doctors to “de-prioritize Varipulse.”
Scott Whitaker sent a letter to the HHS calling for staff cuts at the FDA to be reversed, arguing patient care and U.S. leadership in medtech are on the line.
